Low-flow, low-gradient aortic stenosis

Article written and reviewed by Dr Luca Moretti

Low-flow, low-gradient aortic stenosis is a hemodynamic phenotype in which a calculated valve area in the severe range coexists with velocity and gradient below the thresholds for severe high-gradient stenosis. The apparent contradiction is not an exception to the physics of flow: the pressure difference depends on transvalvular velocity, and velocity depends on the amount of blood ejected per unit time. If flow is reduced, even a critically narrowed orifice may generate a mean gradient below 40 mmHg.

The clinical problem is not simply to recognize a low gradient. It is necessary to establish whether the valve is truly severely stenotic, whether the small area results from technical error or loading conditions, whether low flow results from stenosis or from cardiomyopathy or other lesions, and whether symptoms are attributable to the obstruction. Misclassification can deny potentially lifesaving valve replacement or, conversely, expose a patient with pseudo-severe stenosis and predominant myocardial disease to an unnecessary procedure.

The classical form combines low flow, low gradient and reduced ejection fraction, whereas the paradoxical form maintains an ejection fraction of at least 50% despite reduced stroke volume. The normal-flow, low-gradient pattern belongs to the same diagnostic problem of discordance, but does not meet the definition of LFLG and in most cases behaves like moderate stenosis; before assigning a category, measurements should therefore be corrected and blood pressure, rhythm and hemodynamic conditions documented.

Prevalence estimates vary because thresholds, echocardiographic quality and study populations differ. Among patients with valve area no greater than 1.0 cm², low-gradient phenotypes account for a substantial proportion in valve-center practice; aging increases the prevalence of hypertension, atrial fibrillation, concomitant regurgitation, amyloidosis and kidney disease, all conditions capable of reducing flow and complicating causal attribution.

Classification, etiology and pathophysiology

The classical form is present when stroke volume index is no greater than 35 mL/m², mean gradient is below 40 mmHg, valve area is no greater than 1.0 cm² and ejection fraction is below 50%. Reduced contractility does not represent a single mechanism: it may be the end stage of pressure overload, ischemic cardiomyopathy, post-infarction damage, nonischemic cardiomyopathy or a combination.

When severe stenosis has already impaired the ventricle, excess afterload, hypertrophy, subendocardial ischemia and fibrosis reduce myocardial shortening. Stroke volume falls and the gradient falls with it, so Doppler may appear less severe precisely when the ventricle is more compromised; removal of the obstruction may permit recovery if a substantial component of dysfunction reflects still-reversible afterload mismatch.

In other patients, cardiomyopathy precedes or dominates the stenosis. Low flow exerts insufficient opening force on cusps that are thickened but not critically stenotic, so the continuity equation yields a small valve area at rest. This is pseudo-severe stenosis: primary treatment is directed at the myocardium and loading conditions, not at a valve that opens better when flow increases.

The paradoxical form combines the same criteria for area, gradient and low flow with an ejection fraction of at least 50%. The term does not mean that ventricular function is normal. A small cavity with concentric hypertrophy may eject a normal percentage of a reduced end-diastolic volume, generating an insufficient absolute amount of blood; longitudinal strain, contractile reserve and diastolic function may all be impaired.

Chronic hypertension and high arterial afterload promote concentric remodeling and reduced compliance, making filling increasingly dependent on atrial contraction and elevated pressures. In this fragile balance, atrial fibrillation, tachycardia or hypovolemia can rapidly reduce stroke volume and accentuate the low-flow pattern.

Significant mitral or tricuspid regurgitation and right ventricular dysfunction can reduce forward stroke volume across the aortic valve. Atrial fibrillation introduces beat-to-beat variability and loss of atrial contribution. An excessively high heart rate shortens filling, while a very low heart rate reduces minute flow even when stroke volume is preserved.

Transthyretin cardiac amyloidosis not infrequently coexists with calcific stenosis in older adults referred for TAVI. Infiltration causes thickened walls, a small cavity, longitudinal dysfunction, low flow and conduction disorders. Not every low-flow state in an older patient is amyloidosis, but discordance among wall thickness, voltages, strain with apical sparing and extracardiac manifestations justifies a specific diagnostic pathway.

The simplified instantaneous gradient is proportional to four times the square of velocity. For the same anatomical area, reduced flow lowers velocity and decreases the gradient nonlinearly. Effective valve area, however, is not entirely independent of flow: cusp stiffness and opening change with applied force, a principle that allows dobutamine to distinguish a fixed valve from a relatively flexible one.

A stroke volume index of 35 mL/m² is a useful conventional threshold, not a biological divide. Indexing to body surface area may misclassify people with obesity, while stroke volume per beat does not describe ejection duration. Transvalvular flow rate, stroke volume divided by ejection time, adds information; values around or below 200 mL/s have been proposed as reduced flow, but do not replace guideline-validated criteria.

The normal-flow, low-gradient pattern has an index above 35 mL/m², valve area no greater than 1.0 cm², gradient below 40 mmHg and preserved ejection fraction. It often reflects the fact that an area of 1.0 cm² corresponds hemodynamically to a mean gradient of 30-35 mmHg, small body size, underestimation of the outflow tract or Doppler alignment. It is generally moderate stenosis unless convincing multimodality evidence demonstrates severe disease.

An indexed valve area no greater than 0.6 cm²/m² may help in patients with a small body size, but overestimates severity in obesity and does not correct an error in diameter measurement. Stroke volume indexed to body surface area is likewise vulnerable to anthropometric extremes. Decisions should therefore integrate raw and indexed measurements, morphology and myocardial consequences.

Anatomical severity of the valve and clinical severity do not necessarily coincide: truly severe stenosis with low flow may generate a modest gradient despite advanced damage, whereas moderate stenosis may be poorly tolerated by a markedly dysfunctional ventricle. Valve replacement reduces valvular load, but does not erase myocardial scar or comorbidities that limit recovery.

Clinical manifestations

Dyspnea and reduced exercise capacity are the most common manifestations, but in older adults they have limited specificity. History-taking should therefore reconstruct walking speed, number of flights climbed, need for pauses, recent decline and reasons for reduced activity: a person who progressively avoids exertion may describe themselves as asymptomatic despite already adapting their life to the disease.

In the classical form, signs of heart failure with reduced ejection fraction often predominate: fatigue, hypotension, cool extremities, oliguria, pulmonary congestion, edema and advanced weight loss. Angina may result from coronary artery disease or oxygen imbalance in hypertrophied myocardium. Syncope or presyncope may be hemodynamic, arrhythmic or multifactorial.

In the paradoxical form, preserved ejection fraction may lead to underestimation of disease. Patients may have exertional dyspnea, intolerance to volume changes, pulmonary edema during hypertension or atrial fibrillation, and symptoms consistent with heart failure with preserved ejection fraction. The small cavity limits stroke-volume reserve and high filling pressures arise even at modest workloads.

The small delayed carotid pulse and systolic murmur radiating to the neck may be less evident than in high-gradient stenosis. Lower flow reduces murmur intensity and duration; a soft murmur does not exclude critical obstruction. A diminished second heart sound, fourth heart sound and sustained apical impulse are suggestive, whereas a third heart sound and diffuse apical impulse suggest advanced dysfunction.

Examination should seek concomitant causes of low flow: irregular rhythm, mitral and tricuspid murmurs, jugular venous distension, signs of right ventricular dysfunction, orthostatic hypotension and hydration status. Elevated blood pressure increases global load and should be measured during echocardiography; very low pressure may indicate end-stage disease or excessive treatment.

Anemia, chronic lung disease, obesity, kidney disease, deconditioning and frailty may explain or amplify dyspnea. The presence of an alternative cause does not prove that stenosis is harmless. Attribution requires comparison of valve severity, ventricular response, symptom chronology and results of functional testing or biomarkers.

Coronary artery disease is common in the classical form and may be both a cause of dysfunction and a precipitating factor. It should be assessed before choosing between TAVI and surgery when indicated. Extensive ischemia or transmural scar reduces the likelihood of recovery of ejection fraction, but does not demonstrate that confirmed severe stenosis should remain untreated.

BNP and NT-proBNP reflect wall stress and filling pressures, but also increase with age, atrial fibrillation and kidney disease. Very high or rising values support heart failure and worse prognosis, but do not by themselves distinguish true from pseudo-severe stenosis. Chronic troponin elevation may reflect myocardial injury and does not necessarily indicate an acute coronary syndrome.

Frailty, cognitive disability, nutritional status, renal and hepatic function and noncardiac life expectancy are part of the clinical assessment. Procedural risk is not equivalent to a surgical score, and benefit is not equivalent to technical success. The goal is to predict survival with acceptable quality, functional recovery and the rehabilitation burden.

In the classical phenotype, a history of infarction, revascularization or cardiomyopathy helps estimate how much dysfunction preceded the stenosis. In the paradoxical phenotype, a long history of hypertension, left atrial enlargement and episodes of heart failure with preserved ejection fraction are common. These profiles guide interpretation but do not replace demonstration of valve severity.

Functional testing is considered only in stable patients who report being asymptomatic and after risk assessment. Exercise testing is not used to quantify LFLG valve area and should not be performed in already symptomatic severe stenosis; it can, however, document symptoms, blood-pressure response and exercise capacity when the history is uncertain.

Signs of low perfusion, narrow pulse pressure and intolerance to vasodilators suggest limited reserve, but are influenced by medications and arterial function. Clinical judgment should avoid two opposite shortcuts: considering every stenosis with a soft murmur nonsevere or attributing every manifestation of heart failure to the valve.

Investigations and differential diagnosis

Transthoracic echocardiography is the starting point, and the first step is quality control. Continuous-wave Doppler should seek the highest velocity from apical, right parasternal, suprasternal and other useful windows; misalignment underestimates velocity and gradient. The mean gradient should be traced over the complete envelope, avoiding ectopic and nonrepresentative beats.

The outflow tract diameter is the most error-sensitive measurement because it is squared. It should be measured at the correct site and cardiac phase, without including calcium or choosing an oblique plane. The pulsed-wave Doppler sample should be placed where flow is laminar, before acceleration; moving it too close to the valve overestimates stroke volume, while placing it too far below may underestimate it.

The continuity equation combining outflow tract area, outflow tract velocity-time integral and aortic velocity-time integral provides valve area. Serial studies should preserve method and laboratory when possible. The dimensionless index, the ratio of outflow tract VTI to aortic VTI, avoids diameter measurement; a value below 0.25 supports severe stenosis, but still depends on Doppler acquisition and does not resolve every discordance.

In atrial fibrillation, several cycles with comparable RR intervals are averaged; a single beat may misclassify flow and gradient. In sinus rhythm with ectopy, post-extrasystolic beats should be excluded because they artificially increase flow and gradient. Blood pressure, heart rate, hemoglobin and acute clinical conditions should be stabilized whenever possible before assigning a chronic phenotype.

The operational hemodynamic criteria of the 2025 ESC/EACTS guidelines distinguish:

• LFLG with reduced ejection fraction: mean gradient below 40 mmHg, valve area no greater than 1.0 cm², stroke volume index no greater than 35 mL/m² and ejection fraction below 50%.
• LFLG with preserved ejection fraction: mean gradient below 40 mmHg, valve area no greater than 1.0 cm², stroke volume index no greater than 35 mL/m² and ejection fraction at least 50%.
• Normal-flow, low-gradient: mean gradient below 40 mmHg, valve area no greater than 1.0 cm², stroke volume index above 35 mL/m² and ejection fraction at least 50%.

In the reduced-ejection-fraction form, low-dose dobutamine echocardiography is the reference functional test when no contraindication exists. The dose is gradually increased, generally up to 20 µg/kg/min, with measurement at each stage of stroke volume, velocity, mean gradient and valve area. The aim is to increase flow, not to reach the maximal heart rate of an ischemia stress test.

An increase in stroke volume of at least 20% conventionally defines flow reserve. If, during the increase in flow, valve area remains no greater than 1.0 cm² and mean gradient reaches at least 40 mmHg, stenosis is truly severe. If valve area increases above 1.0 cm² and the gradient remains nonsevere, the response supports pseudo-severe stenosis.

Conventional criteria fail when flow increases only slightly or increases enough to modify area but not enough to reach a 40 mmHg gradient. Projected valve area estimates valve area at a standardized flow rate of 250 mL/s: projected AVA = resting AVA + change in AVA/change in flow rate × (250 − resting flow rate). A value no greater than 1.0 cm² supports severe stenosis.

The projected calculation requires sufficient change in flow and consistent measurements at different stages; if flow changes by less than about 15%, the slope is unstable. The formula does not correct errors in outflow tract measurement and should not be extrapolated beyond low-quality data. Interpretation always integrates morphology, calcium and ventricular consequences.

Absence of flow reserve is not equivalent to pseudo-severe stenosis. It means that the ventricle cannot increase stroke volume under dobutamine and limits traditional classification. Historically it was associated with high surgical mortality; in contemporary practice it is not by itself a contraindication to replacement because CT and other information may confirm severity and TAVI offers a less invasive option.

In the preserved-ejection-fraction form, dobutamine is not routinely used: a small cavity, dynamic response and the risk of intracavitary obstruction make interpretation more difficult. After checking measurements and blood pressure, confirmation relies mainly on morphology, the dimensionless index and a noncontrast CT calcium score, which quantifies calcific burden independently of flow.

According to the 2025 ESC/EACTS algorithm, a score above 2000 Agatston units in men or 1200 in women makes severe stenosis likely with sensitivity and specificity around 85%; above 3000 and 1600, respectively, it makes severe disease highly likely. Values below 1600 in men or 800 in women make severe stenosis unlikely. Thresholds are sex-specific because, for the same degree of obstruction, women on average have more fibrosis and less calcium.

Calcium scoring requires synchronized noncontrast acquisition and segmentation excluding calcium from the coronary arteries, mitral annulus and aorta. Bicuspid valves, young age, predominantly fibrotic disease and amyloidosis may produce severe stenosis with less calcium; the result should therefore not be converted into an absolute rule outside validated populations.

Contrast-enhanced CT measures the annulus and outflow tract, which are often elliptical, and may show that the circular geometry assumed by echocardiography underestimates stroke volume and valve area. A hybrid correction should not be indiscriminately mixed with validated echocardiographic thresholds. The same CT study plans access, coronary ostia and calcium distribution if TAVI is pursued.

Cardiac magnetic resonance quantifies volumes and ejection fraction without geometric assumptions, identifies infarction and replacement fibrosis and, with mapping, suggests infiltrative disease. It does not measure calcium and is not the primary reference for gradient, but clarifies the myocardial substrate and expected reversibility. Bone-tracer scintigraphy and monoclonal protein testing are reserved for suspected amyloidosis.

Transesophageal echocardiography clarifies morphology and the outflow tract when transthoracic windows are inadequate, but sedation can alter flow. Simultaneous left ventricular-aortic catheterization is limited to cases in which a clinically decisive discordance persists despite accurate noninvasive imaging; retrograde crossing of the valve should be avoided unless indispensable.

Differential diagnosis includes moderate stenosis with cardiomyopathy, outflow tract measurement error, Doppler misalignment, high arterial impedance, amyloidosis, hypertrophic cardiomyopathy and subaortic obstruction. Severe mitral regurgitation, mitral stenosis, right ventricular dysfunction and pericardial disease reduce flow. The final report should explicitly state which mechanism has been demonstrated and which remains probable.

Treatment and follow-up

No medication can reopen a calcified valve or has been shown to slow progression of stenosis. Medical therapy serves to stabilize heart failure, treat hypertension, ischemia, atrial fibrillation and comorbidities, and create conditions in which measurements and symptoms can be interpreted. It should not become an indefinite delay when stenosis is severe and causes symptoms.

In the classical form, diuretics reduce congestion but excessive depletion further lowers stroke volume. Guideline-directed therapy for heart failure with reduced ejection fraction is initiated and titrated according to tolerance, with particular attention to blood pressure and renal function. Severe stenosis does not automatically prohibit renin-angiotensin system blockers or beta-blockers when indicated, but requires cautious dosing and monitoring.

If dobutamine demonstrates pseudo-severe stenosis, treatment is directed at the cardiomyopathy and the valve is reassessed after optimization and remodeling. Moderate stenosis may still contribute to afterload and carry prognostic significance, but routine replacement of moderate stenosis in heart failure is not an established standard. A repeat study may reclassify the pattern when flow improves.

In symptomatic patients with the classical form and confirmed truly severe stenosis, valve replacement is recommended when the expected benefit is not futile. If flow reserve is present, confirmation is often straightforward; if absent, severe CT calcium, morphology and the overall clinical picture may support intervention. Lack of reserve indicates risk, not prohibition.

In the paradoxical form with preserved ejection fraction, intervention should be considered only after careful confirmation of severity and demonstration that symptoms are likely due to the stenosis. Elevated blood pressure, lung disease, atrial fibrillation and other valve lesions should be integrated into the assessment. Benefit is less straightforward to predict than in high-gradient disease, making Heart Team selection central.

The normal-flow, low-gradient pattern is generally followed as moderate stenosis because most patients do not have severe obstruction. If calcium score, morphology and other parameters clearly demonstrate severe disease, classification is corrected and the decision follows actual clinical risk. It is not appropriate to treat all valve areas no greater than 1.0 cm² as equivalent.

The choice between TAVI and SAVR follows age, life expectancy, procedural risk, transfemoral access, anatomy, coronary artery disease, bicuspid valve, aortopathy and the need for associated procedures. Low flow alone does not dictate the route. Surgery permits revascularization and treatment of the aorta or other valves; TAVI avoids cardiopulmonary bypass and is often attractive in older or frail patients with dysfunction.

TAVI registries show improvement in ejection fraction and survival compared with the natural history even in patients with very poor ventricular function, but residual mortality remains high. Evidence comparing TAVI and SAVR in LFLG subtypes derives largely from observational analyses and subgroups. It should therefore not be converted into a universal preference independent of anatomy and risk.

Significant coronary artery disease is treated according to complexity and the valve strategy. Functional mitral regurgitation may improve after reduction of aortic afterload and ventricular remodeling; a severe primary lesion may require simultaneous correction and favor surgery. The impact of tricuspid regurgitation and right ventricular dysfunction should be discussed before the procedure.

Balloon aortic valvuloplasty is not definitive therapy in adults with calcific disease. It may serve as a bridge in shock, as a hemodynamic test when the contribution of the valve is uncertain, or as preparation for urgent noncardiac surgery in selected cases. Short-lived benefit, restenosis and the risks of regurgitation or embolism limit its use.

After TAVI or SAVR, baseline echocardiography documents prosthetic gradient, regurgitation, ventricular function and pulmonary pressure. Recovery of ejection fraction may be early when afterload mismatch predominates or incomplete in the presence of scar and infiltration. Persistent low flow requires assessment for prosthesis-patient mismatch, leak, prosthetic dysfunction or myocardial disease.

When intervention is not performed, follow-up should be closer than a simple annual visit if severe disease remains possible, symptoms evolve or function is impaired. Clinical review, echocardiography, rhythm, renal function and natriuretic peptides are tailored to risk. Patients and family members should recognize increasing dyspnea, syncope, angina, rapid weight gain and hypotension.

The prognosis of conservatively treated true, severe, symptomatic LFLG stenosis is poor. Replacement improves survival and functional status in appropriate candidates, but myocardial damage, low flow rate, fibrosis, amyloidosis, right ventricular dysfunction, pulmonary hypertension and frailty may limit recovery; absence of flow reserve is associated with higher risk, but by itself does not predict failure to recover after replacement. The decision must distinguish high risk from futility: they are not synonymous.

Complications and clinical pitfalls

The first complication is progressive heart failure. Stenosis, low flow and dysfunction form a cycle in which afterload depresses stroke volume, low stroke volume masks the gradient, and therapeutic delay increases fibrosis and organ damage. Recurrent congestion and hospitalizations mark a high-risk stage.

Cardiogenic shock may be precipitated by ischemia, arrhythmia, infection, anemia, hypertension or excessive diuresis. Low blood pressure compromises coronary and renal perfusion while the ventricle cannot increase output across the fixed orifice. Management requires a center capable of integrating circulatory support, revascularization and urgent valve intervention or bridging.

Atrial fibrillation is particularly poorly tolerated in the paradoxical form: loss of atrial systole and rapid cycles reduce filling of the small cavity. In the classical form, a rapid ventricular response increases demand and reduces perfusion. Cardioversion, rate control and anticoagulation are selected according to stability, duration and thromboembolic risk.

Pulmonary hypertension and right ventricular dysfunction indicate propagation of damage beyond the left ventricle. Tricuspid regurgitation further reduces systemic forward flow and increases hepatic and renal congestion. Once a pulmonary vascular component or severe right ventricular dysfunction is established, recovery after replacement may be incomplete.

Ischemia and ventricular arrhythmias may result from coronary artery disease, hypertrophy and scar. Syncope should not automatically be attributed to the valve: atrioventricular block, tachyarrhythmias, orthostatic hypotension and medications are frequent causes. Nevertheless, exertional syncope in confirmed severe stenosis is a highly significant symptom.

The main preprocedural iatrogenic pitfall is diagnostic delay. Relying on gradient alone, preserved ejection fraction or a soft murmur may lead to classification as moderate disease. The opposite problem is also important: underestimating the outflow tract diameter can make moderate stenosis appear severe and lead to an unnecessary intervention.

Dobutamine may induce arrhythmias, ischemia, hypotension or dynamic obstruction and should be administered with monitoring and expertise. Absent reserve makes conventional criteria inconclusive; forcing high doses to obtain a gradient exposes the patient to risk without answering the diagnostic question. Calcium scoring provides complementary anatomical information in these cases.

Procedural complications are not specific to LFLG, but physiological reserve is smaller. TAVI may cause bleeding, vascular injury, stroke, paravalvular leak, conduction disturbances, coronary obstruction and kidney injury; SAVR may cause bleeding, infection, atrial fibrillation, stroke, kidney injury and low-output syndrome.

Prosthesis-patient mismatch leaves a residual gradient and persistently high afterload, which is particularly harmful in an already dysfunctional ventricle. A small annulus requires planning among surgical enlargement, a supra-annular prosthesis and a transcatheter device. After TAVI, significant leak adds volume overload to a vulnerable myocardium.

Failure of ejection fraction to recover does not demonstrate procedural failure. It may reflect ischemic scar, replacement fibrosis, amyloidosis, mismatch or dysfunction from another cause. Persistent symptoms require reassessment of the prosthesis, coronary arteries, rhythm, other valves, pulmonary pressures, anemia and rehabilitation potential.

Pseudo-severe stenosis follows a different trajectory: risk derives mainly from the cardiomyopathy. If function improves, valve area and gradient may be reclassified; if flow remains low, the pattern remains difficult and requires surveillance. A moderately calcified valve may progress and become truly severe, so the initial diagnosis does not end follow-up.

Assessment of futility should consider terminal illness, advanced dementia, irreversible frailty and lack of foreseeable functional benefit, not merely the fact that the patient is high risk. Shared discussion clarifies goals, probability of survival, potential recovery, rehabilitation and palliative alternatives when replacement would not provide meaningful benefit.